Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Int J Cancer. 2020 Mar 9;147(7):1939–1952. doi: 10.1002/ijc.32937

Table 4:

Primary outcomes of Phase II clinical trials (n=39)

Number Percent
Interventional Model
Single Group Assignment 26 66.7
Parallel Assignment 11 28.2
Not Specified 2 5.1
Treatment Allocation
Non-randomized 30 76.9
Randomized 9 23.1
Masking
Open Label 36 92.3
Masked 1 2.6
Not Specified 2 5.1
Main Primary Endpoint
Progression-free Survival 7 17.9
Objective Response Rate 23 59.0
Clinical Benefit Rate 2 5.1
Relapse Rate 2 5.1
Safety / Toxicity 2 5.1
Efficacy 3 7.7